The cascade of care for household contacts of people with drug-resistant TB

Affiliations

¹ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
² Aurum Institute, Johannesburg, South Africa, School of Public Health, University of Witwatersrand, Johannesburg, South Africa, Department of Medicine, Vanderbilt University, Nashville, TN, USA.
³ Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA.
⁴ Desmond Tutu TB Centre, the Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa.
⁵ Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NB, USA.
⁶ Clinical Trials Research Centre (UZ-CTRC), University of Zimbabwe, Harare, Zimbabwe.
⁷ Socios En Salud Sucursal Peru, Lima, Peru.
⁸ Aurum Institute, Rustenburg, South Africa.
⁹ Byramjee Jeejeebhoy Government Medical College CRS, Johns Hopkins University Baltimore-Washington-India Clinical Trials Unit, Pune, India.
¹⁰ Les Centres GHESKIO, Port-au-Prince, Haiti.
¹¹ Research Division, De La Salle Medical and Health Sciences Institute, Dasmarinas City, Cavite, The Philippines.
¹² Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.

I Gomes et al. Int J Tuberc Lung Dis. 2023.

. 2023 Feb 1;27(2):154-156.

doi: 10.5588/ijtld.22.0473.

¹ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
² Aurum Institute, Johannesburg, South Africa, School of Public Health, University of Witwatersrand, Johannesburg, South Africa, Department of Medicine, Vanderbilt University, Nashville, TN, USA.
³ Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA.
⁴ Desmond Tutu TB Centre, the Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa.
⁵ Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NB, USA.
⁶ Clinical Trials Research Centre (UZ-CTRC), University of Zimbabwe, Harare, Zimbabwe.
⁷ Socios En Salud Sucursal Peru, Lima, Peru.
⁸ Aurum Institute, Rustenburg, South Africa.
⁹ Byramjee Jeejeebhoy Government Medical College CRS, Johns Hopkins University Baltimore-Washington-India Clinical Trials Unit, Pune, India.
¹⁰ Les Centres GHESKIO, Port-au-Prince, Haiti.
¹¹ Research Division, De La Salle Medical and Health Sciences Institute, Dasmarinas City, Cavite, The Philippines.
¹² Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.

No abstract available

Conflict of interest statement

Conflicts of interest: none declared.

1. World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Geneva, Switzerland: WHO, (2020) - PubMed
1. Seddon JA, et al. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). Trials 2018;19(1):1–11. - PMC - PubMed
1. Fox GJ, et al. Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial. BMJ Open 2020;10(1):e033945. - PMC - PubMed
1. clinicaltrials.gov. Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB). NCT03568383. Bethesda, MD, USA: clinicaltrials.gov, 2022. https://clinicaltrials.gov/ct2/show/NCT03568383.
1. Dodd PJ, et al. The global impact of household contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study. Lancet Global Health 2022;10(7):e1034–e1044. - PMC - PubMed